

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 21865-0002001	Application No. 10/718,986
	Applicant Yu et al.		
	Filing Date November 21, 2003	Group Art Unit 1652	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2005/0112751	5/26/2005	Fang et al			
	2	2007/0190163	8/16/2007	Malaknov, M.P. et al.			
	3	2008/0075708	3/27/2008	Yu et al.			
	4	2009/0142327	6/4/2009	Fang et al			
	5						
	6						
	7						
	8						
	9						
	10						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	11	WO93/03708	3/4/1993	WIPO				
	12	WO98/31817	7/23/1998	WIPO				
	13							
	14							
	15							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	16	Ada et al., "Purification and properties of neuraminidase from <i>Vibrio cholerae</i> . <i>J Gen Microbiol</i> 24:409 (1961).
	17	Benet et al., <i>Pharmacological Basis of Therapeutics</i> , 8th ed., Eds. Goodman and Gillman, page 1-32, (1990).
	18	Cardin et al., "Molecular modeling of protein-glycosaminoglycan interactions." <i>Arteriosclerosis</i> 9:21-32 (1989).
	19	Cechechchi et al., "Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5." <i>J Virol</i> 75:8772-80 (2001).
	20	Crennell et al., "Crystal structure of a bacterial sialidase (from <i>Salmonella typhimurium</i> LT2) shows the same fold as an influenza virus neuraminidase." <i>Proceedings of the National Academy of Sciences of the United States of America</i> 90:9852-9856 (1993).

Examiner Signature /Tekchand Saidha/ (05/11/2010)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 21865-0002001	Application No. 10/718,986
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Yu et al.	
		Filing Date November 21, 2003	Group Art Unit 1652

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	21	Ernst et al., "Enzymatic degradation of glycosaminoglycans." <i>Critical Rev Biochem Mol Bio</i> 30:387-444 (1995).
	22	Finlay and Falkow, "Common Themes in Microbial Pathogenicity," <i>Microbiological Reviews</i> , 210-230 (1989).
	23	Granoff & Webster, R. G., ed. <i>Encyclopedia of Virology, 2nd Edition</i> , Vol 2.
	24	Guibinga et al., "Cell surface heparin sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells." <i>Molecular Therapeutics</i> 5:538-46 (2002).
	25	Ishibashi et al., "Probiotics and safety," <i>The American Journal of Clinical Nutrition</i> 73: 465S-470S (2001)
	26	Jones et al., <i>Journal of Neuropathology and Experimental Neurology</i> 57(2): 140-157 (1998).
	27	Loomes et al., "Erythrocyte receptors for Mycoplasma pneumoniae are sialylated oligosaccharides of Ii antigen type", <i>Nature</i> 307:560-563 (1994).
	28	Loveless et al., "Sialo-Oligosaccharide Receptors for Mycoplasma pneumoniae and Related Oligosaccharides of Poly-N-Acetylactosamine Series Are Polarized at the Cilia and Apical-Microvillar Domains of the Ciliated Cells in Human Bronchial Epithelium" <i>Infection and Immunity</i> 57(4):1285-1289 (1989)
	29	MacEachran et al., "Adhesion of Pseudomonas aeruginosa to human buccal spithelial cells: evidence for two classes of receptors", <i>Canadian J. Microbiol.</i> 31:563-569 (1985).
	30	Marcus et al. "Adherence of Pseudomonas aeruginosa to Tracheal Epithelium", <i>Infection and Immunity</i> . 57:1050-1053 (1989).
	31	Meuller T.D., et al., "Structure, binding and antagonists in the IL-4/IL-13 receptor system. <i>Biochimica et Biophysica Acta</i> 1592:237-250 (2002).
	32	NCBI Protein AAH09799 (3 pgs.) (accessed on 09.19.2007)
	33	Neumann, G., et al., "Generation of Influenza A viruses entirely from cloned cDNAs." <i>Proceedings of the National Academy of Sciences of the United States of America</i> 96:9345-9350 (1999).
	34	Plowman, G. D., "The Amphiregulin Gene Encodes a Novel Epidermal Growth Factor-Related Protein with Tumor-Inhibitory Activity," <i>Molecular and Cellular Biology</i> 10(5):1969-1981 (1990).
	35	Powell et al., Attachment of Mycoplasma pneumoniae to Respiratory Epithelium., <i>Infection and Immunity</i> 13(3):959-966 (1976).
	36	Roberts et al., "Regulation of Lymphocyte Proliferation After Influenza Virus Infection of Human Mononuclear Leukocytes", <i>Journal of Medical Virology</i> , 27:179-187 (1989).
	37	Sobeslavsky et al., "Adsorption of Mycoplasma pneumoniae to Neuraminic Acid Receptors of Various Cells and Possible Role in Virulence," <i>Journal of Bacteriology</i> 96(3):695-705 (1968).
	38	Suzuki et al., "Receptor Specificities of Human Respiroviruses", <i>Journal of Virology</i> 75(10):4604-4613 (2001).
	39	Thorne, et al., "The Heparin-Binding Domain of Amphiregulin Necessitates the Precursor Pro-Region for Growth Factor Secretion," <i>Mol. Cell. Biol.</i> , 14:1635-1646 (1994)
	40	Umeda et al., "Activity of Human Erythrocyte Gangliosides as a Receptor to HVJ", <i>Virology Vol.</i> 133:172-182 (1984).
	41	Vishwanath et al., "Tracheobronchial Mucin Receptor for Pseudomonas auruginosa: Predominance of Amino Sugars in Binding Sites", <i>Infection and Immunity</i> 48:331-335 (1985).
Examiner Signature /Tekchand Saidha/ (05/11/2010)		Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 21865-0002001	Application No. 10/718,986
		Applicant Yu et al.	
		Filing Date November 21, 2003	Group Art Unit 1652

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	42	Vlasak et al., "Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses," <i>Proceedings of the National Academy of Sciences of the United States of America</i> 85:4526-4529 (1988).
	43	Wills-Karp et al., "Interleukin-13 in asthma." <i>Curr Opin Pulm Med</i> 9:21-27 (2003).
	44	Wybenga et al., "Glycophorin as a Receptor for Sendai Virus", <i>Biochemistry</i> 35:9513-9518 (1996).
	45	Non-final Office action dated 4/21/2009 for U.S. Application Serial No. 10/939,262.
	46	Final Office action dated 10/24/2008 for U.S. Application Serial No. 10/939,262.
	47	Non-final Office action dated 3/26/2008 for U.S. Application Serial No. 10/939,262.
	48	Non-final Office action dated 5/22/2007 for U.S. Application Serial No. 10/939,262.
	49	Non-final Office action dated 12/18/2008 for U.S. Application Serial No. 11/893,621.

Examiner Signature /Tekchand Saidha/ (05/11/2010)	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./